منابع مشابه
Meropenem pharmacokinetics in the newborn.
We studied meropenem in 23 pre-term (gestational age, 29 to 36 weeks) and 15 full-term (gestational age, 37 to 42 weeks) neonates. Meropenem doses of 10, 20, and 40 mg/kg were administered as single doses (30-min intravenous infusion) on a random basis. Blood was obtained for determining the meropenem concentration nine times. Each child required other antimicrobials for proven/suspected bacter...
متن کاملPharmacokinetic and pharmacodynamic properties of meropenem.
Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens. Although minimum inhibitory concentration (MIC) data reflect microbial susceptibility to an antibiotic, they do not provide dosing information. The integration of pharmacokinetic and microbiological data, however, can be used to design rational dosing strategies. Meropenem is a br...
متن کاملMeropenem-induced myoclonus: A case report
A 61-year-old woman was seen at the intensive care unit because of myoclonic status. Her medical history included arterial hypertension, dyslipidemia and diabetes. In the previous year she had been hospitalized because of dilated cardiomyopathy (ejection fraction 21%) and non-sustained ventricular tachycardia. At that time she was managed with an implantable cardiac defibrillator. On this admis...
متن کاملClinical Pharmacology of Meropenem in Neonates: Effects and Pharmacokinetics
Meropenem, a carbapenem antibiotic, has a broad-spectrum activity and is active against Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influencae, Moraxella catarrhalis, gram-negative enteric bacilli as Escherichia coli, Klebsiella, Enterobacter, Serratia and Pseudomonas aeruginosa. Meropenem has excellent penetration in body tissues and in cerebrospinal fluid (in the presenc...
متن کاملMeropenem resistance in imipenem-susceptible meropenem-resistant Klebsiella pneumoniae isolates not detected by rapid automated testing systems.
Klebsiella pneumoniae showing high resistance to all β-lactams except imipenem, designated as ISMRK (imipenem-susceptible meropenem-resistant Klebsiella) is emerging in Japan. The carbapenem resistance of ISMRK cannot be screened by the Vitek and the RAISUS rapid automated susceptibility test systems, which may lead to inappropriate antimicrobial therapy, resulting in compromised patient outcomes.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-95887-z